Onward is the leader in the spinal cord stimulation space. They focus on targeted, programmed stimulation of the spinal cord to restore movement and other functions, alone or in combination with BCIs for thought-driven movement. Representing some of our most mature technologies, their first FDA approval is on track with the device going to market in 2024.
Portfolio
Unlocking potential
We follow a rigorous scientific diligence process and only invest in companies with the greatest potential to commercialize therapies and impact people's lives.
Axonis Therapeutics is developing medicines for neuron restoration and neuromodulation. Therapies are aimed at enabling neural tissue to resist degeneration, restore healthy electrical balance, and promote neural regeneration. Successful pre-clinical POC studies have been completed, and a clinical trial is planned for 2024 / 25.
Sania has developed a gene-therapy platform to selectively target dysfunctional neural circuits in a more selective and safer manner than previously possible. The company has demonstrated in-vivo proof of concept and is preparing for IND-enabling studies.
Augmental has developed the MouthPad^: an in-mouth interface for hands-free human-computer interaction. The technology gives people living with paralysis their independence back. It is already being used in early-access mode and partnerships for distribution are underway.
EG 427 has developed a platform technology to create targeted gene therapies tailored to specific neuronal populations implicated in major pathologies. The first indication is in neurogenic detrusor overactivity (NDO), a form of spastic bladder common in SCI and neurodegenerative conditions such as multiple sclerosis and Parkinson's with significant impact on a person's quality of life and high risk of secondary complications.
Healx is one of the few AI - based discovery companies that have successfully shown the power of their approach across multiple indications from neuroscience to oncology. Their lead program for neurofibromatosis type 1 (NF1) is already in Ph2, within only 4 years of starting the discovery program. SCI Ventures and Healx have partnered to create a neuro-regeneration program with a focus on chronic SCI.
In the press
